SAD and MAD Study of AKB-9090 in Healthy Adult Participants

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2026
This is a first-in-human (FIH study designed to evaluate safety, tolerability, pharmacokinetic, and pharmacodynamic effects of AKB-9090 in healthy adult participants. The study consists of two stages: Stage 1, a single ascending dose (SAD) phase with five dose cohorts, and Stage 2, a multiple ascending dose (MAD) phase with three dose cohorts. Approximately 40 participants in SAD and 30 in MAD are planned to be enrolled.
Epistemonikos ID: f9f7fa8937cde32a1e847b4a9e3f032f87e7f879
First added on: Feb 25, 2026